drugset / Trial / NCT02896335
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2
Recruiting
45 enrolled
Massachusetts General Hospital
Merck Sharp & Dohme LLC · collabPfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.
Timeline
- Start
- 2017-02-02
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |